Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Busy address KBO
17 other companies have their registered office at the same address; threshold 10.
Financials
Financial year 2025
Obulytix from Gent, company number BE0803351624, closed financial year 2025 with a result of € -2.7 million after tax. For that financial year Obulytix recorded a gross margin of € -2.1 million and equity of € 2.2 million. Compared with financial year 2024, the result moved from € -1.1 million to € -2.7 million. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 2.2 million
▼ 42% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -2.7 million
▼ 146 % more loss than in 2024
Profit after tax over the fiscal year.
€ 1.9 million
▲ 28% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -3.7 million.
People and assets in 2025
4.3
▲ 1.7 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 300,683
▲ 19% vs 2024
€ 69,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 27,491
▲ 161% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 2.3 million
Loans from banks and other lenders, long and short.
€ 337,216
▲ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 75,582
▲ 180% vs 2024
Taxes, VAT and social contributions still to pay.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € -590,450 | € -2,121,140 | ▼ € 1.5 million |
| Profit after taxes | € -1,081,154 | € -2,664,969 | ▼ € 1.6 million |
| Equity | € 3,820,634 | € 2,217,512 | ▼ 42% |
| Total debts | € 1,280,995 | € 3,077,165 | ▲ 140% |
| Cash | € 1,513,358 | € 1,931,033 | ▲ 28% |
| Retained profit | € -1,081,154 | € -3,746,123 | ▼ € 2.7 million |
| Bank debt | € 0 | € 2,250,000 | |
| Balance sheet total | € 5,101,630 | € 5,294,677 | ▲ 4% |
| Employees (FTE) | 2.6 | 4.3 | ▲ 1.7 |
Key figures of Obulytix, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Obulytix?
What happened at Obulytix in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Lisa Patel stepped down as director. NBB
- New annual accounts for financial year 2025: loss of € 2.7 million. Source: NBB ↗
- Philipp Müller became a director. NBB
- Niklas Czeloth stepped down as director. NBB
- Lisa Patel became a director. NBB
- Biotilia BV became a director. NBB
- Bram Perdu became a director. NBB
- Dominic De Groote became a director. NBB
In short
From € 1.1 million loss in 2024 to € 2.7 million loss in 2025.
Management
The stake of QBIC III FUND comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
ObulytixBehind Obulytix are Yves Briers, Biotilia BV, Philipp Müller, Bram Perdu, Dominic De Groote and Qbic Venture Partners III NV. The shares are held by QBIC III FUND (21.4%).
Directors
According to the 2025 annual accounts
since 2023
Managing director · represented by Kristof Van Emelen
since 2024
Philipp Müller
Director
since 2025
Bram Perdu
Director
since 2023
Dominic De Groote
Director
since 2023
Director · represented by Cédric Van Nevel
Also active at: RheaVita, VoxelSensors, AnimAb, AmphiStar, weave.ly, Swave, QBIC III FUND, THERAtRAME +2 more
since 2023
Lisa Patel
Director
since 2025 · until 2031
Niklas Czeloth
Director
since 2023 · until 2025
Shareholders
21.4%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Suzanne Tassierstraat 1 box 3.4
9052 Gent
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 17 companies are registered at this address.
All companies at this address →VLAAMS INSTITUUT VOOR BIOTECHNOLOGIE - FLANDERS INSTITUTE FOR BIOTECHNOLOGY
€ 52.6 million revenue · 2025
ORIONIS BIOSCIENCES
€ 11.6 million revenue · 2025
LO²CUS Gent
€ 1.7 million gross margin · 2024
S-Biomedic
€ 4.4 million gross margin · 2025
VIB BIO-INCUBATOR
€ 536,162 gross margin · 2025
+12 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0803.351.624
- VAT number
- BE 0803.351.624
- Registered office
- Suzanne Tassierstraat 1 bus 3.4, 9052 Gent
- Names & denominations
- Obulytix
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 29 June 2023
- Peppol
- Active · Active since 28 Aug 2025
- Activities · NACE
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Vervaardiging van geneesmiddelen
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied